Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung BioLogics Faces Penalties As Authorities Conclude 'Intentional' Accounting Violation

Executive Summary

Things have turned for the worse for Samsung BioLogics after a second review by financial authorities in South Korea over its accounting related to corporate control over Samsung Bioepis, resulting in fines, a recommendation for dismissal of its CEO, and a suspension in trading in its stock. The company is poised to face tough times ahead, although it reiterates it hasn’t violated any accounting rules and has vowed again to seek legal steps.


Related Content

Samsung BioLogics Vows Improved Management Transparency As Stock Resumes Trade
Authorities Find Accounting Violation By Samsung BioLogics, Prosecutors To Probe


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts